The oncology landscape is increasingly recognizing that the future of cancer treatment may depend just as much on immune engagement and combination strategies as on standalone therapeutic activity.
That shift in thinking is shaping much of the scientific attention surrounding pelareorep, the lead immunotherapeutic candidate being advanced by Oncolytics (NASDAQ: ONCY).
For years, oncology drug candidates were largely evaluated through…
